Press Releases

 
Press Releases
  Date Title and Summary View
Feb 10, 2014
SAN DIEGO, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today the closing of its previously announced initial public offering of 1,900,000 shares of common stock, at a public offering price of $10.00 per share. The gross proceeds to Biocep...
Feb 4, 2014
SAN DIEGO, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc., an oncology diagnostics company focused on improving individual patient treatment, today announced the pricing of its initial public offering of 1,900,000 shares of its common stock offered at a price to the public of $10.00 per share. The gross proceeds to Biocept from the initial public o...
Nov 5, 2013
SAN DIEGO, November 5, 2013 — Biocept, Inc., today announced the appointment of Marsha A. Chandler, Ph.D. and Bruce A. Huebner as independent directors. Dr.  Chandler is currently the Executive Vice President and Chief Operating Officer of the Salk Institute for Biological Studies. She manages approximately 1000 scientific and...
Sep 10, 2013
Biocept, Inc. announced today that it has appointed Michael W. Nall as President and Chief Executive Officer. Mr. Nall’s extensive commercialization, sales and marketing experience will be a significant asset as the company brings its pipeline of OncoCEETM cancer diagnostic tests to the market. Mr. Nall has more than 25 years of le...
Jun 4, 2013
San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in cancer patients, reported the publication in the journal Cancer Medicine of a paper entitled “Discordance in HER2 gene ampli...
May 29, 2012
San Diego, California – Biocept, Inc., a CLIA-certified laboratory testing company focused on oncology diagnostics, specifically the detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced that with collaborators from Columbia University Medical Center and the MD Anderson Cancer Center, it will present three ...
Apr 2, 2012
San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced that it will be presenting three posters at the 103nd Annual Meeting of the American Association for Cancer Research, being held in Chicago Marc...
Feb 20, 2012
San Diego, California – Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells (CTCs) in cancer patients, announced that two of its senior scientists, Farideh Bischoff, Ph.D., Vice President of Translational Research, and Lyle Arnold, Ph.D., Senior Vice Presid...
Feb 7, 2012
San Diego and Aliso Viejo, California: – Biocept, Inc., a privately-held laboratory services company focused on Circulating Tumor Cells (CTCs), and Clarient, Inc., a GE Healthcare Company, announced today the US commercial launch of Biocept’s proprietary breast cancer CTC test, OncoCEE-BRTM, which is performed on a blood sample. Onco...
Dec 14, 2011
San Diego, California – Biocept, Inc., a privately?held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells in cancer patients, announced today the publication of a paper on research performed with collaborators from the University of Texas MD Anderson Cancer Center entitled “Novel ...
Page: FirstPrevious ...
17
NextLast
= add release to Briefcase